27838149|t|Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine
27838149|a|The anti-folate pemetrexed is a radiosensitizer. In pre-clinical models, pemetrexed is more effective along with the base-excision-repair inhibitor methoxyamine. We tested whether methoxyamine enhances pemetrexed -mediated radiosensitization of lung adenocarcinoma cells and xenografts. A549 and H1299 cells were evaluated for cell cycle distribution by flow cytometry, radiosensitization by clonogenic assay, and DNA repair by neutral comet assay and repair protein activation. H460 cells were included in some studies. Xenografts in nude mice received drug (s) and/or radiation, and tumor growth was monitored by caliper and in vivo toxicity by animal weight. Exposure to pemetrexed / methoxyamine for 24 (H1299, H460) or 48 (A549)hours before irradiation resulted in accumulation of cells near the radiosensitive G1/S border; dose - enhancement factors of 1.62±0.19, 1.97±0.25, and 1.67±0.30, respectively; reduction of mean inactivation dose by 32%, 30%, and 46%, respectively; and significant reductions of SF2 and SF4 (p<0.05). Radiosensitization was associated with rapid DNA double-strand-break rejoining and increased levels of DNA-PKcs. Both tumor-growth rate and tumor-growth delay were significantly improved by adding methoxyamine to pemetrexed pre-irradiation (p<0.0001); no mice lost weight during treatment. Addition of methoxyamine to pemetrexed and fractionated radiotherapy may improve outcome for patients with locally advanced non-squamous non-small-cell lung cancer.
27838149	0	18	Radiosensitization	T061	C0279024
27838149	22	48	non-small-cell lung cancer	T191	C0007131
27838149	49	54	cells	T025	C0334227
27838149	59	69	xenografts	T061	C0520484
27838149	77	96	interactive effects	T169	C1704675
27838149	100	110	pemetrexed	T109,T121	C0210657
27838149	115	127	methoxyamine	T109,T121	C0066156
27838149	132	143	anti-folate	T121	C1254351
27838149	144	154	pemetrexed	T109,T121	C0210657
27838149	160	175	radiosensitizer	T121	C0034541
27838149	180	199	pre-clinical models	T170	C1514292
27838149	201	211	pemetrexed	T109,T121	C0210657
27838149	220	229	effective	T080	C1704419
27838149	245	265	base-excision-repair	T045	C1158530
27838149	266	275	inhibitor	T080	C1999216
27838149	276	288	methoxyamine	T109,T121	C0066156
27838149	293	299	tested	T169	C0039593
27838149	308	320	methoxyamine	T109,T121	C0066156
27838149	321	329	enhances	T052	C2349975
27838149	330	340	pemetrexed	T109,T121	C0210657
27838149	351	369	radiosensitization	T061	C0279024
27838149	373	392	lung adenocarcinoma	T191	C0152013
27838149	403	413	xenografts	T061	C0520484
27838149	415	419	A549	T025	C4277577
27838149	424	435	H1299 cells	T025	C0334227
27838149	455	465	cell cycle	T043	C0007586
27838149	466	478	distribution	T169	C1704711
27838149	482	496	flow cytometry	T059	C0016263
27838149	498	516	radiosensitization	T061	C0279024
27838149	520	536	clonogenic assay	T059	C0041372
27838149	542	552	DNA repair	T045	C0012899
27838149	556	575	neutral comet assay	T063	C0751980
27838149	580	594	repair protein	T044	C1159338
27838149	595	605	activation	T045	C0599177
27838149	607	617	H460 cells	T025	C0334227
27838149	649	659	Xenografts	T061	C0520484
27838149	663	672	nude mice	T015	C0025932
27838149	673	686	received drug	T033	C0332154
27838149	698	707	radiation	T070	C0851346
27838149	713	725	tumor growth	T191	C0598934
27838149	743	750	caliper	T074	C0175720
27838149	755	762	in vivo	T062	C0681829
27838149	763	771	toxicity	T037	C0600688
27838149	775	788	animal weight	T032	C0005910
27838149	790	801	Exposure to	T080	C0332157
27838149	802	812	pemetrexed	T109,T121	C0210657
27838149	815	827	methoxyamine	T109,T121	C0066156
27838149	836	841	H1299	T025	C0334227
27838149	843	847	H460	T025	C0334227
27838149	856	860	A549	T025	C4277577
27838149	874	885	irradiation	T070	C1282930
27838149	898	910	accumulation	T033	C4055506
27838149	914	919	cells	T025	C0334227
27838149	929	955	radiosensitive G1/S border	T082	C1254362
27838149	957	961	dose	T081	C0178602
27838149	964	975	enhancement	T052	C2349975
27838149	976	983	factors	T169	C1521761
27838149	1056	1068	inactivation	T169	C0544461
27838149	1069	1073	dose	T081	C0178602
27838149	1162	1180	Radiosensitization	T061	C0279024
27838149	1207	1240	DNA double-strand-break rejoining	T045	C3155842
27838149	1265	1273	DNA-PKcs	T116,T126	C0212694
27838149	1280	1292	tumor-growth	T191	C0598934
27838149	1293	1297	rate	T079	C0449249
27838149	1302	1314	tumor-growth	T191	C0598934
27838149	1315	1320	delay	T079	C0205421
27838149	1359	1371	methoxyamine	T109,T121	C0066156
27838149	1375	1385	pemetrexed	T109,T121	C0210657
27838149	1386	1401	pre-irradiation	T070	C1282930
27838149	1417	1421	mice	T015	C0025932
27838149	1441	1450	treatment	T169	C1522326
27838149	1464	1476	methoxyamine	T109,T121	C0066156
27838149	1480	1490	pemetrexed	T109,T121	C0210657
27838149	1545	1553	patients	T101	C0030705
27838149	1576	1615	non-squamous non-small-cell lung cancer	T191	C2585890